Thanks for finding us at EAU

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases


​​​​​Thanks for finding us at EAU

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Highlights From Your Congress


 

Patient Perspectives Abstracts


Abstract Title: Remote consultations: experiences of patients with prostate cancer
Authors: Rebecca Leszczynski, Steve Allen, Raj Persad, Toby Page, William Cross, Emma Craske, Henry Lovett, Karen Stalbow
Sponsor: Pfizer
Study: PCUK Study
Disposition: Oral (Top 5), July 9 16:30 – 17:40, Patient Poster Session


Abstract Title: Accrual of African American Men Into Prostate Cancer Clinical Trials: Collaborations to Incorporate Patient Perspectives
Authors: Thomas Farrington, Jake Vinson, Keith Crawford
Sponsor: Pfizer
Study: PHEN Study
Disposition: Oral, July 9 16:30 – 17:40, Patient Poster Session

What’s Of Interest


Pfizer Oncology Collaborating to Improve Patient Centricity

Investigator Resources

Focus on Health Equity

Commitment To Oncology


Scheduled Events


Abstract Title:

Remote consultations: experiences of patients with prostate cancer
Authors: Rebecca Leszczynski, Steve Allen, Raj Persad, Toby Page, William Cross, Emma Craske, Henry Lovett, Karen Stalbow
Sponsor: Pfizer
Study: PCUK Study
Disposition: Oral (Top 5), July 9 16:30 – 17:40, Patient Poster Session


Abstract Title:

Accrual of African American Men Into Prostate Cancer Clinical Trials: Collaborations to Incorporate Patient Perspectives​​​​​​​
Authors: Thomas Farrington, Jake Vinson, Keith Crawford
Sponsor: Pfizer
Study: PHEN Study​​​​​​​
Disposition: Oral, July 9 16:30 – 17:40, Patient Poster Session


Poster Title:

Enzalutamide PROSPER
Poster Description: Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of PROSPER
Authors:
Marc-Oliver Grimm, Maha Hussain, Arnulf Stenzl, Tilman Todenhöfer, Gabriel P. Haas, Jennifer Sugg, Reinhard Brauner, Marco Groß-Langenhoff, Cora N. Sternberg
Sponsor: Astellas

Opportunities To Connect


Connect with Pfizer
through our Contact Form

Medical Information​​​​​​​

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.